Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine have uncovered significant findings regarding the impact of transthyretin, or TTR, protein ...

Many forms of amyloidosis are caused by mutations in very specific genes that cause the misfolding of certain proteins, which ultimately misfold and aggregate. Though genetic diseases are normally not ...

Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare condition that may cause polyneuropathy (nerve damage). If you have a family history or symptoms, your doctor may order tests to check ...

Over 140 pathogenic variants in the TTR gene are associated with the rare and progressive autosomal dominant inherited form of amyloidosis, hereditary transthyretin amyloidosis. Across all genotypes ...

-ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients ...

When the Human Genome Project concluded 21 years ago, it opened the door for genetic testing and a promise for lifesaving screenings and personalized medicine. An innovation that serves as a key ...

Genetic testing can be a fearful, daunting, overwhelming, exciting, or joyful experience. In many cases, the emotions of people who pursue genetic testing can be described with more than just one of ...

Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine led a nationwide study to examine the role of carpal tunnel syndrome in predicting the risk of ...

Please provide your email address to receive an email when new articles are posted on . Roughly 3% of the Black U.S. population are carriers of an ATTR amyloidosis-causing gene. Among all carriers ...